Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 482 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 Talking With Your Doctor About Negative Emotions During Cancer November 3, 2020 For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to... August 29, 2022 EMA Recommends Granting a Marketing Authorisation for Nirogacestat July 3, 2025 Load more HOT NEWS Why Keeping Up With Your Cancer Screening Is So Important Handmade Artisan Gifts For Under $30 New Research in Treating Metastatic Breast Cancer, Preventing Breast Cancer, and... Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell...
